GH
Guardant Health, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$148.07-5.00%
Price as of Jul 20, 2026
GH financials
Guardant Health, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M |
| Cost of revenue | $349.0M | $289.8M | $227.1M | $156.3M |
| Gross profit | $633.0M | $449.2M | $336.9M | $293.2M |
| Operating expenses | $1.1B | $892.8M | $901.6M | $837.6M |
| Operating income | -$436.3M | -$443.6M | -$564.7M | -$544.4M |
| Net income | -$416.3M | -$436.4M | -$479.4M | -$654.6M |
| EBITDA | -$373.9M | -$390.1M | -$433.3M | -$614.9M |
| Basic EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 |
| Diluted EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 |
| Balance sheet | ||||
| Cash & equivalents | $378.2M | $525.5M | $1.1B | $141.6M |
| Total assets | $2.0B | $1.5B | $1.8B | $1.6B |
| Total liabilities | $2.1B | $1.6B | $1.6B | $1.5B |
| Stockholders’ equity | -$99.3M | -$139.6M | $158.7M | $60.2M |
| Total debt | $1.7B | $1.3B | $1.4B | $1.4B |
| Net debt | $1.3B | $810.5M | $220.2M | $1.2B |
| Cash flow | ||||
| Operating cash flow | -$184.8M | -$239.9M | -$325.0M | -$309.5M |
| Capital expenditure | -$48.3M | -$35.1M | -$20.5M | -$77.5M |
| Free cash flow | -$233.1M | -$274.9M | -$345.5M | -$386.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $13.6M | $0.00 | $0.00 | $0.00 |